• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Labeling updates and warnings through November 2008 for efalizumab (Raptiva)

Article

Labeling updates and warnings through November 2008 for efalizumab (Raptiva)

A boxed warning has been added to the labeling information for efalizumab (Raptiva, Genentech), which is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. This warning highlights the risk of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), occurring in patients treated with efalizumab. Infections that have been observed in efalizumab-treated patients include bacterial sepsis, viral meningitis, invasive fungal disease, PML, and other opportunistic infections.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.